' '
Deutsch | English    

Forschungsdatenbank PMU-SQQUID

A Gene Gun-mediated Nonviral RNA trans-splicing Strategy for Col7a1 Repair.
Peking, P; Koller, U; Hainzl, S; Kitzmueller, S; Kocher, T; Mayr, E; Nyström, A; Lener, T; Reichelt, J; Bauer, JW; Murauer, EM;
Mol Ther Nucleic Acids. 2016; 5: e287
Originalarbeiten (Zeitschrift)


Bauer Johann
Ebner Patricia
Hainzl Stefan
Kocher Thomas
Koller Ulrich
Lener Thomas
Mayr Elisabeth
Murauer Eva Maria
Reichelt Julia


RNA trans-splicing represents an auspicious option for the correction of genetic mutations at RNA level. Mutations within COL7A1 causing strong reduction or absence of type VII collagen are associated with the severe skin blistering disease dystrophic epidermolysis bullosa. The human COL7A1 mRNA constitutes a suitable target for this RNA therapy approach, as only a portion of the almost 9 kb transcript has to be delivered into the target cells. Here, we have proven the feasibility of 5" trans-splicing into the Col7a1 mRNA in vitro and in vivo. We designed a 5" RNA trans-splicing molecule, capable of replacing Col7a1 exons 1-15 and verified it in a fluorescence-based trans-splicing model system. Specific and efficient Col7a1 trans-splicing was confirmed in murine keratinocytes. To analyze trans-splicing in vivo, we used gene gun delivery of a minicircle expressing a FLAG-tagged 5" RNA trans-splicing molecule into the skin of wild-type mice. Histological and immunofluorescence analysis of bombarded skin sections revealed vector delivery and expression within dermis and epidermis. Furthermore, we have detected trans-spliced type VII collagen protein using FLAG-tag antibodies. In conclusion, we describe a novel in vivo nonviral RNA therapy approach to restore type VII collagen expression for causative treatment of dystrophic epidermolysis bullosa.

Find related publications in this database (Keywords)

epidermolysis bullosa
in situ therapy
nonviral minicircle plasmid
RNA trans-splicing correction
type VII collagen